

04 Aug 2024 | News

Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast edition of Five Must-Know Things: Pfizer bullish on its oral glp-1; BMS's rising confidence about Medicare pricing of Eliquis; more long term data for Leqembi; NewAmsterdam's CETP inhibitor shows promise; and a look at Mankind's Bharat Serums buy.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 2 August 2024, including: [Pfizer Inc.](#) bullish on its oral GLP-1; [Bristol Myers Squibb Company's](#) rising confidence about Medicare pricing of Eliquis; more long term data for Leqembi; [NewAmsterdam Pharma BV's](#) CETP inhibitor shows promise; and a look at [Mankind Pharma Ltd.'s Bharat Serums And Vaccines Limited \(BSV\)](#) buy.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Pfizer Bullish On Danuglipron's Position In Oral GLP-1 Race](#)" - Scrip, 30 Jul, 2024.)

(Also see "[BMS 'Increasingly Confident' It Can Handle The Impact Of Medicare Pricing For Eliquis](#)" - Scrip, 26 Jul, 2024.)

(Also see "[Time Is On Eisai's Side As More Long-Term Data Emerge For Leqembi](#)" - Scrip, 30 Jul, 2024.)

(Also see "[*CETP Gets Another Go: NewAmsterdam Phase III Trial Shows Safety And Efficacy*](#)" - Scrip, 29 Jul, 2024.)

(Also see "[*\\$1.6bn Bharat Serums Buy Gives Mankind Dominance In Women's Health, R&D Engine*](#)" - Scrip, 29 Jul, 2024.)

[Click here to explore this interactive content online](#) ✨